[go: up one dir, main page]

HUP0104330A2 - EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristályos formái, előállításukra szolgáló eljárás, azokat hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristályos formái, előállításukra szolgáló eljárás, azokat hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP0104330A2
HUP0104330A2 HU0104330A HUP0104330A HUP0104330A2 HU P0104330 A2 HUP0104330 A2 HU P0104330A2 HU 0104330 A HU0104330 A HU 0104330A HU P0104330 A HUP0104330 A HU P0104330A HU P0104330 A2 HUP0104330 A2 HU P0104330A2
Authority
HU
Hungary
Prior art keywords
aze
cgl
pab
compound
crystalline forms
Prior art date
Application number
HU0104330A
Other languages
English (en)
Inventor
Daniel Edvardsson
Lena Hedström
Anita Lundblad
Ursula Pettersson
Original Assignee
Astrazeneca Ab,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, filed Critical Astrazeneca Ab,
Publication of HUP0104330A2 publication Critical patent/HUP0104330A2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A tal lm ny t rgy t az E<>tO2C-CH2-(R)Cgl-Aze-Pab-OH képletűvegyületnek vagy ennek gyógyszerészetileg elfogadható sóinaklényegében krist lyos form i képezik. Ezek a krist lyos form kvízmentesek lehetnek vagy legfeljebb 2 t"meg% vizet tartalmazhatnak.Az E<>tO2C-CH2-(R)Cgl-Aze-Pab-OH képletű vegyület krist lyos form ijóval nagyobb kémiai és szil rd llapotbeli stabilit st mutatnak, mintaz amorf form ban elő llított vegyület. Ugyancsak a tal lm ny t rgy tképezi a fenti vegyület vagy ennek gyógyszerészetileg elfogadható sóielő llít sra szolg ló elj r s, azokat hatóanyagként tartalmazógyógyszerkészítmények, valamint trombin inhibitorként t"rténő alkalmazsuk. Ó
HU0104330A 1998-09-03 1999-09-02 EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristályos formái, előállításukra szolgáló eljárás, azokat hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk HUP0104330A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802974A SE9802974D0 (sv) 1998-09-03 1998-09-03 New crystalline forms
PCT/SE1999/001514 WO2000014110A1 (en) 1998-09-03 1999-09-02 CRYSTALLINE FORMS OF EtO2C-CH2-(R)Cgl-Aze-Pab-OH

Publications (1)

Publication Number Publication Date
HUP0104330A2 true HUP0104330A2 (hu) 2002-04-29

Family

ID=20412468

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104330A HUP0104330A2 (hu) 1998-09-03 1999-09-02 EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristályos formái, előállításukra szolgáló eljárás, azokat hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk

Country Status (39)

Country Link
US (5) US6225287B1 (hu)
EP (1) EP1107980B1 (hu)
JP (2) JP3493341B2 (hu)
KR (1) KR100629825B1 (hu)
CN (1) CN1204143C (hu)
AP (1) AP1520A (hu)
AR (1) AR029312A1 (hu)
AT (1) ATE231521T1 (hu)
AU (1) AU763421B2 (hu)
BG (1) BG105384A (hu)
BR (1) BR9913464A (hu)
CA (1) CA2341259A1 (hu)
CU (1) CU23015A3 (hu)
CZ (1) CZ2001775A3 (hu)
DE (1) DE69905054T2 (hu)
DK (1) DK1107980T3 (hu)
EA (1) EA003264B1 (hu)
EE (1) EE200100135A (hu)
ES (1) ES2192101T3 (hu)
HK (1) HK1034721A1 (hu)
HR (1) HRP20010132B1 (hu)
HU (1) HUP0104330A2 (hu)
ID (1) ID28779A (hu)
IL (1) IL141433A0 (hu)
IS (1) IS1942B (hu)
MY (1) MY121394A (hu)
NO (1) NO20011083L (hu)
NZ (2) NZ510070A (hu)
OA (1) OA11908A (hu)
PL (1) PL346544A1 (hu)
SA (1) SA99200682B1 (hu)
SE (1) SE9802974D0 (hu)
SK (1) SK2802001A3 (hu)
TR (1) TR200100700T2 (hu)
TW (1) TWI247013B (hu)
UA (1) UA66869C2 (hu)
WO (1) WO2000014110A1 (hu)
YU (1) YU17301A (hu)
ZA (1) ZA200101763B (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
SE9902550D0 (sv) 1999-07-02 1999-07-02 Astra Ab New crystalline forms
US20020115603A1 (en) * 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
US7645864B2 (en) * 2000-10-12 2010-01-12 Chugai Seiyaku Kabushiki Kaisha Erythromycin derivative having novel crystal structures and processes for their production
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
DE50310038D1 (de) 2002-03-11 2008-08-07 Curacyte Ag Hemmstoffe der urokinase, ihre herstellung und verwendung
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
DE10342108A1 (de) * 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
WO2005031397A2 (en) * 2003-09-26 2005-04-07 Zetetic Institute Catoptric and catadioptric imaging systems with pellicle and aperture-array beam-splitters and non-adaptive and adaptive catoptric surfaces
US20050209211A1 (en) * 2004-03-16 2005-09-22 Devalina Law Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir
WO2005091696A1 (fr) * 2004-03-29 2005-10-06 Quanta Display Inc. Structure a cadres pour module retroeclaire
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
EP2062909A1 (en) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
EP2361572B1 (en) * 2010-02-26 2013-04-17 Biedermann Technologies GmbH & Co. KG Implant for stabilizing bones or vertebrae
US9550585B2 (en) 2014-06-09 2017-01-24 Space Systems/Loral, Llc Highly inclined elliptical orbit de-orbit techniques

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1075277B (it) * 1977-02-11 1985-04-22 Erba Carlo Spa Derivati insaturi e epossidici dell'acio 7-acilamido-3-cefem-4-carbossilico e procedimento per la loro preparazione
US4315011A (en) * 1978-07-12 1982-02-09 Richter Gedeon Vegyeszeti Gyar Rt. 1-Alkyl-9-bromohexahydroindolo quinolizium salts and use thereof to increase blood flow
GB2096988B (en) * 1980-11-20 1984-08-01 Beecham Group Ltd Aromatic hydroxyamines
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE504185C2 (sv) * 1994-11-08 1996-12-02 Astra Ab Lagringsstabil vattenlösning för infusion av trombininhibitorer
TW541316B (en) * 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
US5830805A (en) * 1996-11-18 1998-11-03 Cornell Research Foundation Electroless deposition equipment or apparatus and method of performing electroless deposition
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms

Also Published As

Publication number Publication date
NO20011083D0 (no) 2001-03-02
US6888007B2 (en) 2005-05-03
JP2004075687A (ja) 2004-03-11
CZ2001775A3 (cs) 2001-10-17
ES2192101T3 (es) 2003-09-16
PL346544A1 (en) 2002-02-11
AR029312A1 (es) 2003-06-25
DE69905054T2 (de) 2003-11-06
SA99200682B1 (ar) 2006-08-22
CN1325406A (zh) 2001-12-05
UA66869C2 (uk) 2004-06-15
OA11908A (en) 2006-04-10
TWI247013B (en) 2006-01-11
KR20010088795A (ko) 2001-09-28
US20050054579A9 (en) 2005-03-10
US20010023244A1 (en) 2001-09-20
DE69905054D1 (de) 2003-02-27
ZA200101763B (en) 2002-06-03
JP2002524467A (ja) 2002-08-06
US20060287249A1 (en) 2006-12-21
DK1107980T3 (da) 2003-04-22
BG105384A (en) 2001-11-30
KR100629825B1 (ko) 2006-09-29
EE200100135A (et) 2002-06-17
CA2341259A1 (en) 2000-03-16
HK1034721A1 (en) 2001-11-02
CU23015A3 (es) 2005-01-25
CN1204143C (zh) 2005-06-01
TR200100700T2 (tr) 2001-07-23
WO2000014110A1 (en) 2000-03-16
MY121394A (en) 2006-01-28
ID28779A (id) 2001-07-05
YU17301A (sh) 2004-05-12
AP2001002078A0 (en) 2001-03-31
NO20011083L (no) 2001-05-03
US6440939B2 (en) 2002-08-27
US20030017992A1 (en) 2003-01-23
EP1107980A1 (en) 2001-06-20
EP1107980B1 (en) 2003-01-22
EA200100194A1 (ru) 2001-10-22
AP1520A (en) 2005-12-28
NZ510070A (en) 2003-04-29
HRP20010132B1 (en) 2004-06-30
US20050153901A1 (en) 2005-07-14
SK2802001A3 (en) 2001-09-11
US6225287B1 (en) 2001-05-01
AU6014799A (en) 2000-03-27
IL141433A0 (en) 2002-03-10
HRP20010132A2 (en) 2002-02-28
IS5870A (is) 2001-02-28
NZ524486A (en) 2004-10-29
IS1942B (is) 2004-08-13
JP3493341B2 (ja) 2004-02-03
BR9913464A (pt) 2001-06-12
SE9802974D0 (sv) 1998-09-03
ATE231521T1 (de) 2003-02-15
EA003264B1 (ru) 2003-02-27
AU763421B2 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
HUP0104330A2 (hu) EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristályos formái, előállításukra szolgáló eljárás, azokat hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk
EP0378255A3 (en) 2-aminopyrimidinone derivatives
HUP0001383A1 (hu) N-(Aril/heteroaril)-aminosav-származékok, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
PT84218B (pt) Processo para a preparacao de 5,6-dihidro-2-(fenilo substituido)-1,2,4-triazina -3,5(2h,4h)-dionas e de composicoes farmaceuticas que as contem
SE9701304D0 (sv) Compounds
IL95956A0 (en) Benzoic acid derivatives and pharmaceutical compositions containing the same
EP1193269A4 (en) CRYSTALLINE 1-METHYLCARBAPENEM DERIVATIVES
MX9204637A (es) Nuevos derivados de pirazina y procedimiento para su preparacion.
SE9401005L (sv) Farmaceutisk komposition med analgetisk aktivitet
WO2002000166A3 (en) New compounds useful as antibacterial agents
SI0861250T1 (en) Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
HU901617D0 (en) Herbicide compositions containing {[(1,3,5-triazin-2-yl)-amino-carbonyl]-amino-sulfonyl}-benzoic acid esters and process for the preparation of the active ingredients
HUP9802897A2 (hu) Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény
AU614204B2 (en) 16-hydroxymethyl amphotericin b derivatives
ES8605493A1 (es) Un procedimiento para la preparacion de un derivado de acido 2-anilino, 6,1-dihidro-6-oxo-5-pirimidincarboxilico.
ES2104938T3 (es) Metodo de inhibir la fibrosis.
ES2000907A6 (es) Procedimiento de preparar compuestos 2-oxaisocefen microbiologicamente activos
ATE50248T1 (de) Ein imidazolidintrion-derivat oder ein seiner pharmazeutisch akzeptierbaren salze enthaltende pharmazeutische zusammenstellung.
HUP0004432A2 (hu) (R)-3-{[(4-Fluorfenil)szulfonil]amino}-1,2,3,4-tetrahidro-9H-karbazol-9-propánsav (ramatroban) termodinamikailag stabil formája és a vegyületet tartalmazó gyógyászati készítmény
NO983217L (no) Terapeutiske anti-astmamidler som inneholder selenforbindeler
NO950177D0 (no) Farmakologisk aktive erivater
SE8303719L (sv) Eburnan-oximderivat, forfarande for framstellning derav samt farmaceutiska kompositioner innehallande dessa foreningar
RU94036762A (ru) Гетероарилпиперидины, способ их получения, промежуточные соединения синтеза и фармацевтическая композиция
JPS5746915A (en) Antiallergic agent
KR940703656A (ko) 에이즈 바이러스 감염 저해용 조성물